Pfizer has inked a groundbreaking pricing agreement with the White House to offer certain drugs at most-favored-nation pricing, aligning U.S. medication costs with lower prices in other developed countries. The deal introduces a direct-to-consumer website, TrumpRx, facilitating discounted access to Pfizer medications, with cash prices averaging 50% below list price. Pfizer’s CEO Albert Bourla praised the agreement as a step towards greater affordability, while the administration aims to roll out further drug pricing initiatives. This deal has triggered stock rallies and market speculation on the broader industry impact amid ongoing political negotiations. However, some pricing specifics and coverage nuances remain to be clarified.